Apatinib Mesylate
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Atypical/malignant Meningioma
Conditions
Recurrent Atypical/malignant Meningioma
Trial Timeline
Aug 18, 2020 → Aug 31, 2025
NCT ID
NCT04501705About Apatinib Mesylate
Apatinib Mesylate is a pre-clinical stage product being developed by Brain Biotech for Recurrent Atypical/malignant Meningioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04501705. Target conditions include Recurrent Atypical/malignant Meningioma.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04501705 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Recurrent Atypical/malignant Meningioma